Related Experiment Videos
[Tuberculosis in patients undergoing hemodialysis]
Toshinobu Yokoyama1, Toru Rikimaru, Rumi Gohara
1First Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume-shi, Fukuoka 830-0011, Japan. yokoyama-t@nyc.odn.ne.jp
Insights
Patients on hemodialysis with active tuberculosis show depressed cellular immunity. Prompt recognition of peripheral neuropathy and pyridoxine use are crucial for favorable outcomes in these tuberculosis patients.
Area of Science:
- Nephrology
- Immunology
- Infectious Diseases
Context:
- Tuberculosis (TB) incidence and mortality are elevated in hemodialysis patients.
- Hemodialysis patients at Kurume University Hospital were assessed for active TB.
- Immunologic and clinical features of TB in hemodialysis patients were investigated.
Purpose:
- To investigate the immunologic and clinical characteristics of active tuberculosis in patients undergoing hemodialysis.
- To evaluate the outcomes of antitubercular chemotherapy in this patient population.
Summary:
- Cellular immunity is impaired in hemodialysis patients with TB, indicated by reduced lymphocytes and anergy to purified protein derivative (PPD) skin tests.
- Hemodialysis may reduce interferon-gamma (IFN-gamma) levels in some patients.
- Despite higher general risks, favorable clinical outcomes were observed in this study's cohort.
- Peripheral neuropathy must be promptly identified and managed with pyridoxine to prevent complications.
Impact:
- Highlights the importance of monitoring immune status in hemodialysis patients with TB.
- Emphasizes the need for vigilant management of potential side effects like peripheral neuropathy.
- Suggests that with appropriate care, active TB in hemodialysis patients can have a positive prognosis.
Abstract:
We studied patients who were diagnosed as active tuberculosis while undergoing hemodialysis at Kurume University Hospital. The observation included immunologic and clinical features. Cellular immunity was depressed in our patients undergoing hemodialysis, as evident from the decreased numbers of lymphocytes and anergy to tuberculin skin tests with purified protein derivative (PPD). Further, in a few patients, hemodialysis was shown to eliminate IFN-gamma from the blood. Various antituberculous chemotherapy regimens have been studied in hemodialysis patients. Although the incidence and mortality of tuberculosis have been reported to be higher in hemodialysis patients than in the general population, the clinical outcome of our cases was favorable in this study. One important notice is to recognize promptly peripheral neuropathy while treating tuberculosis associated with hemodialysis, and this could be prevented by the adequate use of pyridoxine.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Hemodialysis II: Procedure and Complications
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Hemodialysis III: Nursing Management
Hemodialysis I: Introduction